160 related articles for article (PubMed ID: 23553575)
21. The neurobiology of attention-deficit/hyperactivity disorder.
Chamberlain SR; Robbins TW; Sahakian BJ
Biol Psychiatry; 2007 Jun; 61(12):1317-9. PubMed ID: 17556026
[No Abstract] [Full Text] [Related]
22. Effects of stimulants and atomoxetine on cortisol levels in children with ADHD.
Isaksson J; Hogmark Å; Nilsson KW; Lindblad F
Psychiatry Res; 2013 Oct; 209(3):740-1. PubMed ID: 23850434
[TBL] [Abstract][Full Text] [Related]
23. Atomoxetine ameliorates nocturnal enuresis with subclinical attention-deficit/hyperactivity disorder.
Ohtomo Y
Pediatr Int; 2017 Feb; 59(2):181-184. PubMed ID: 27501068
[TBL] [Abstract][Full Text] [Related]
24. Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence.
Prasad S; Steer C
Paediatr Drugs; 2008; 10(1):39-47. PubMed ID: 18162007
[TBL] [Abstract][Full Text] [Related]
25. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
[TBL] [Abstract][Full Text] [Related]
26. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.
Cottrell S; Tilden D; Robinson P; Bae J; Arellano J; Edgell E; Aristides M; Boye KS
Value Health; 2008; 11(3):376-88. PubMed ID: 18489664
[TBL] [Abstract][Full Text] [Related]
27. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
[TBL] [Abstract][Full Text] [Related]
28. Updates on attention deficit hyperactivity disorder, child abuse and neglect, and sudden infant death syndrome.
Daley KC
Curr Opin Pediatr; 2003 Apr; 15(2):216-25. PubMed ID: 12640282
[No Abstract] [Full Text] [Related]
29. Attention-deficit/hyperactivity disorder and enuresis: a study about effectiveness of treatment with methylphenidate or desmopressin in a pediatric population.
Ferrara P; Sannicandro V; Ianniello F; Quattrocchi E; Sbordone A; Petitti T; Mariotti P
Minerva Pediatr; 2019 Apr; 71(2):135-138. PubMed ID: 28260347
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study.
Kemner JE; Starr HL; Ciccone PE; Hooper-Wood CG; Crockett RS
Adv Ther; 2005; 22(5):498-512. PubMed ID: 16418159
[TBL] [Abstract][Full Text] [Related]
31. Atomoxetine-associated hemospermia: a case report.
Raj YP
J Clin Psychiatry; 2008 Jul; 69(7):1189. PubMed ID: 18687023
[No Abstract] [Full Text] [Related]
32. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.
Kratochvil CJ; Heiligenstein JH; Dittmann R; Spencer TJ; Biederman J; Wernicke J; Newcorn JH; Casat C; Milton D; Michelson D
J Am Acad Child Adolesc Psychiatry; 2002 Jul; 41(7):776-84. PubMed ID: 12108801
[TBL] [Abstract][Full Text] [Related]
33. Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis.
Hazell PL; Kohn MR; Dickson R; Walton RJ; Granger RE; Wyk GW
J Atten Disord; 2011 Nov; 15(8):674-83. PubMed ID: 20837981
[TBL] [Abstract][Full Text] [Related]
34. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
Prescrire Int; 2010 Feb; 19(105):5-8. PubMed ID: 20455329
[TBL] [Abstract][Full Text] [Related]
35. Current pharmacotherapy of attention deficit hyperactivity disorder.
Reddy DS
Drugs Today (Barc); 2013 Oct; 49(10):647-65. PubMed ID: 24191257
[TBL] [Abstract][Full Text] [Related]
36. Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety.
Bushe CJ; Savill NC
J Psychopharmacol; 2014 Mar; 28(3):204-11. PubMed ID: 23438503
[TBL] [Abstract][Full Text] [Related]
37. The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care.
McCarthy S; Wilton L; Murray ML; Hodgkins P; Asherson P; Wong IC
BMC Pediatr; 2012 Jun; 12():78. PubMed ID: 22712630
[TBL] [Abstract][Full Text] [Related]
38. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
[TBL] [Abstract][Full Text] [Related]
39. Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD.
Starr HL; Kemner J
J Natl Med Assoc; 2005 Oct; 97(10 Suppl):11S-16S. PubMed ID: 16350601
[TBL] [Abstract][Full Text] [Related]
40. Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands.
Sasané R; Hodgkins P; Meijer W
Curr Med Res Opin; 2010 Nov; 26(11):2565-74. PubMed ID: 20863165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
